

Alfaxan[®] Multidose

(alfaxalone) 10 mg/mL injectable anesthetic

**Alfaxan[®]
Multidose**

Indicated for induction and
maintenance of anesthesia

56

FDA approved for 56
days of use
after broaching



Alfaxan[®] Multidose

Comorbidities and other risk factors add uncertainty to outcomes

Alfaxan® Multidose (alfaxalone) - proceed with confidence

What is Alfaxan® Multidose?

Alfaxan® Multidose contains alfaxalone, a neuroactive steroid molecule that does not bind to sex hormone, glucocorticoid or mineralcorticoid receptors.¹

Alfaxan® Multidose has the same effectiveness, versatility and wide safety profile as original Alfaxan®, but with a non-irritating preservative that allows the product to be used for up to 56 days after the vial is broached and stored at room temperature.



Alfaxan® Multidose
FDA approved for 56 days
of use after broaching

Effectiveness

Quick, anxiety-free unconsciousness^{2,3,4,5} with muscle relaxation^{2,3} allows rapid intubation and transition to maintenance anesthesia

- Rapid onset of anesthesia^{2,3,6} (usually within 60 seconds)
- Works reliably with all premedicants
- The use of premedicants may reduce the Alfaxan® Multidose induction dose

Versatility

- FDA-approved for use in dogs AND cats
- Use for induction AND maintenance of anesthesia
- Use confidently among **healthy populations**, **special populations** (brachycephalic patients⁷, sighthounds⁸, C-sections⁹ and juvenile dogs¹⁰ and cats¹¹)
- Clinically acceptable induction agent in sick dogs (ASA III-V¹²)



- ▶ Helps maintain acceptable cardiovascular and respiratory parameters
- ▶ Wide safety margin
- ▶ Approved for use in kittens at least 4 weeks of age and puppies at least 10 weeks old
- ▶ Safety demonstrated in cats and dogs in multiple peer-reviewed publications^{12,13}
- ▶ Alfaxalone does not accumulate¹⁴. Administer repeat boluses to maintain anesthesia
- ▶ No pain upon injection IV and non irritating to tissue^{15,16}

Rapid recoveries - the final step to a positive outcome



Rapid drug elimination and quick recoveries reunite the patient and client sooner, so you and your staff can assist other patients.

- ▶ Alfaxalone is structurally similar to progesterone
- ▶ Metabolized in the liver
- ▶ Inactive metabolites excreted in the bile and urine
- ▶ Average time to extubation after discontinuation of maintenance anesthesia \approx 15 minutes
- ▶ Average time to standing after extubation \approx 20 minutes



Alfaxan® Multidose (alfaxalone)

General dosing instructions for dogs and cats

Dose	Dog	Maintenance of Anesthesia	Cat	Maintenance of Anesthesia
Induction	2 mg/kg	5-10 mins	5 mg/kg	15-30 mins
Maintenance	1.5-2.2 mg/kg	6-8 mins	1.4-1.5 mg/kg	3-5 mins

Approved dosing ranges for dogs and cats, with and without premedication

Premedication	Average Alfaxan® Multidose Induction Dose (and range) in mg/kg	
	Dog	Cat
No premedication	2.2 (1.5 – 4.5)	4.0 (2.2 – 9.7)
Benzodiazepine + opioid + acepromazine	1.7 (0.9 – 3.5)	2.3 (1.2 – 5.0)
Opioid + acepromazine	1.6 (0.6 – 3.5)	3.2 (1.1 – 10.8)
Alpha 2-agonist	1.1 (0.2 – 2.0)	3.6 (1.1 – 5.0)
(See full prescribing information, including some other combinations of premedications)		

IMPORTANT SAFETY INFORMATION: Alfaxan Multidose (for cats and dogs) and Alfaxan Multidose IDX (for minor species) is not for human use. Exercise caution to avoid accidental self-injection. Overdose is likely to cause cardiorespiratory depression (such as hypotension, bradycardia and/or apnea). Avoid contact of this product with skin, eyes, and clothes. Contains alfaxalone, a neurosteroid anesthetic and a class IV controlled substance, which has an abuse potential similar to other Schedule IV sedatives. Alfaxan Multidose is contraindicated in cats, dogs and minor species with a known sensitivity to Alfaxan Multidose or its components, or when general anesthesia and/or sedation are contraindicated. Do not use in any minor species animal that may become eligible for consumption by humans or food-producing animals. Patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. Rapid bolus administration or anesthetic overdose may cause cardiorespiratory depression, including hypotension, apnea, hypoxia, or death. Arrhythmias may occur secondary to apnea and hypoxia. In cases of anesthetic overdose, stop Alfaxan Multidose administration and administer treatment as indicated by the patient's clinical signs. Careful monitoring of the patient is necessary due to possibility of rapid arousal. Alfaxan Multidose has not been evaluated in pregnant, lactating, and breeding cats or in cats less than 4 weeks of age, dogs less than 10 weeks of age, or in debilitated patients. See full Prescribing Information for Alfaxan Multidose and Alfaxan Multidose IDX, attached.

1. Data on file: TI-09528 Zoetis 2010. 2. Muir W, Lerche P, Wiese A, Nelson L, Pasloske K, Whittam T. Cardiorespiratory and anesthetic effects of clinical and supraclinical doses of alfaxalone in dogs. *Vet Anaesth Analg*. 2008;35(6):451-462. 3. Muir W, Lerche P, Wiese A, Nelson L, Pasloske K, Whittam T. The cardiorespiratory and anesthetic effects of clinical and supraclinical doses of alfaxalone in cats. *Vet Anaesth Analg*. 2009;36(1):42-54. 4. Pasloske K, Gazzard B, Perkins N, Dunlop C, & Whittam T. A multicentre clinical trial evaluating the efficacy and safety of Alfaxan-CD RTU administered to dogs for induction and maintenance of anaesthesia. In British Small Animal Veterinary Congress, 2005:556. 5. Pasloske K, Gazzard B, Perkins N, Dunlop C, & Whittam T. A multicentre clinical trial evaluating the efficacy and safety of Alfaxan administered to cats for induction and maintenance of anaesthesia. In British Small Animal Veterinary Congress, 2007:166. 6. Ferré PJ, Pasloske K, Whittam T, Ranasinghe MG, Li Q, Lefebvre HP. Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTU. *Vet Anaesth Analg*. 2006;33(4):229-236. 7. Norgate D, Ter Haar G, Kulendra N, Veres-Nyeki KO. A comparison of the effect of propofol and alfaxalone on laryngeal motion in nonbrachycephalic and brachycephalic dogs. *Vet Anaesth Analg*. 2018;45(6):729-736. 8. Pasloske K, Sauer B, Perkins N, Whittam T. Plasma pharmacokinetics of alfaxalone in both premedicated and unpremedicated Greyhound dogs after single, intravenous administration of Alfaxan at a clinical dose. *J Vet Pharmacol Ther*. 2009;32(5):510-513. 9. Metcalfe S, Hulands-Nave A, Bell M, et al. Multicentre, randomised clinical trial evaluating the efficacy and safety of alfaxalone administered to bitches for induction of anaesthesia prior to caesarean section. *Aust Vet J*. 2014;92(9):333-338. 10. O'Hagan B, Pasloske K, McKinnon C, Perkins N, Whittam T. Clinical evaluation of alfaxalone as an anaesthetic induction agent in dogs less than 12 weeks of age. *Aust Vet J*. 2012;90(9):346-350. 11. O'Hagan BJ, Pasloske K, McKinnon C, Perkins N, Whittam T. Clinical evaluation of alfaxalone as an anaesthetic induction agent in cats less than 12 weeks of age. *Aust Vet J*. 2012;90(10):395-401. 12. Psatha E, Alibhai HJ, Jimenez-Lozano A, Armitage-Chan E, Brodbelt DC. Clinical efficacy and cardiorespiratory effects of alfaxalone, or diazepam/fentanyl for induction of anaesthesia in dogs that are a poor anaesthetic risk. *Vet Anaesth Analg*. 2011;38(1):24-36. 13. Schnell M, Weiss C, & Heit M. Margin of Safety of the Anesthetic Alfaxan-CD RTU Dogs at 0, 1, 3 and 5X the Intravenous Dose of 2 mg/kg. *Am Coll Vet Intern Med*. In 22nd Annual Forum, Minneapolis, MN 2004:849. 14. Whittam T, Pasloske KS, Heit MC, Ranasinghe MG. The pharmacokinetics and pharmacodynamics of alfaxalone in cats after single and multiple intravenous administration of Alfaxan at clinical and supraclinical doses. *J Vet Pharmacol Ther*. 2008;31(6):571-579. 15. Pasloske K, Ranasinghe MG, Sauer S, Hare J. The bioequivalence of a single intravenous administration of the anesthetic alfaxalone in cyclodextrin versus alfaxalone in cyclodextrin plus preservatives in cats. *J Vet Pharmacol Ther*. 2018;41(3):437-446. 16. Data on file: AR-20794 Zoetis 2015

zoetis

FOR ANIMAL USE ONLY

Alfaxan® Multidose

(alfaxalone) 10 mg/mL
Intravenous injectable anesthetic for use in cats and dogs.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION
ALFAXAN MULTIDOSE (alfaxalone) is a neuroactive steroid molecule with properties of a general anesthetic. Alfaxalone is chemically described as 3- α -hydroxy-5- α -pregnane-11, 20-dione, and has a molecular weight of 332.5. The primary mechanism for the anesthetic action of alfaxalone is modulation of neuronal cell membrane chloride ion transport, induced by binding of alfaxalone to GABA_A (gamma-aminobutyric acid) cell surface receptors.

INDICATIONS
ALFAXAN MULTIDOSE is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs.

DOSAGE AND ADMINISTRATION
Administer by intravenous injection only. For induction, administer ALFAXAN MULTIDOSE over approximately 60 seconds or until clinical signs show the onset of anesthesia, titrating administration against the response of the patient. Rapid administration of ALFAXAN MULTIDOSE may be associated with an increased incidence of cardiorespiratory depression or apnea. Apnea can occur following induction or after the administration of maintenance boluses of ALFAXAN MULTIDOSE. The use of preanesthetics may reduce the ALFAXAN MULTIDOSE induction dose. The choice and the amount of phenothiazine, alpha₂-adrenoreceptor agonist, benzodiazepine or opioid will influence the response of the patient to an induction dose of ALFAXAN MULTIDOSE.

When using ALFAXAN MULTIDOSE, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.

ALFAXAN MULTIDOSE contains preservatives. Use within 56 days of first puncture. Any unused ALFAXAN MULTIDOSE remaining after 56 days should be discarded.

ALFAXAN MULTIDOSE should not be mixed with other therapeutic agents prior to administration.

CATS
Induction of general anesthesia in cats: Induction dose guidelines are based on data from the field study (see EFFECTIVENESS) and range between 2.2 - 9.7 mg/kg for cats that did not receive a preanesthetic, and between 1 - 10.8 mg/kg for cats that received a preanesthetic. The alfaxalone induction dose in the field study was reduced by 10 - 43%, depending on the combination of preanesthetics (dose sparing effect). Dose sparing of ALFAXAN MULTIDOSE will depend on the potency, dose, and time of administration of the various preanesthetics that are used prior to induction. To avoid anesthetic overdose, titrate the administration of ALFAXAN MULTIDOSE against the response of the patient.

Anesthesia is usually observed within 60 seconds after the start of injection, and permits intubation within 1 - 2 minutes, irrespective of preanesthetic. The duration of anesthesia from a single induction dose ranges between 15 - 30 minutes in the unpreanesthetized cat. If a preanesthetic is used, anesthetic duration may be longer, depending on the class and dose of preanesthetic. Individual anesthesia times vary.

Examples from the field study of average induction doses (and ranges) for cats that received various preanesthetics are presented as dosing guidelines in the table. The table is for guidance only. Draw up the maximum expected target dose and administer to effect. The actual induction dose should be based on patient response.

Alfaxalone Induction Dose Guidelines: CATS

Preanesthetic	Average alfaxalone induction dose and range (mg/kg)	Number of cats
No preanesthetic	4 (2.2 - 9.7)	33
Opioid + phenothiazine	3.2 (1.1 - 10.8)	96
Benzodiazepine + phenothiazine	3.6 (1.5 - 7.1)	23
Benzodiazepine + opioid + phenothiazine	2.3 (1.2 - 5)	26
Alpha ₂ -adrenergic agonist with/without phenothiazine	3.6 (1.1 - 5)	15
Alpha ₂ -adrenergic agonist + phenothiazine with/without benzodiazepine or opioid	2.9 (1 - 3.9)	11

Additional doses of ALFAXAN MULTIDOSE similar to those used for maintenance (1.1 - 1.5 mg/kg) may be administered to facilitate intubation.

Maintenance of general anesthesia in cats: Following induction of anesthesia with ALFAXAN MULTIDOSE and intubation, anesthesia may be maintained using intermittent ALFAXAN MULTIDOSE intravenous boluses or an inhalant anesthetic agent. A maintenance bolus containing 1.1 - 1.3 mg/kg provides an additional 7 - 8 minutes of anesthesia in preanesthetized cats. A dose of 1.4 - 1.5 mg/kg provides an additional 3 - 5 minutes anesthesia in unpreanesthetized cats. Clinical response may vary, and is determined by the dose, rate of administration, and frequency of maintenance injections.

ALFAXAN MULTIDOSE maintenance dose sparing is greater in cats that receive a preanesthetic. Examples from the field study of maintenance doses for preanesthetized and unpreanesthetized cats are presented as guidelines in the table. Maintenance dose and frequency should be based on the response of the individual patient.

Alfaxalone Maintenance Dose Guidelines: CATS

Dose and Duration	Preanesthetized cats	Unpreanesthetized cats
Maintenance anesthesia doses	1.1 - 1.3 mg/kg	1.4 - 1.5 mg/kg
Mean duration of anesthesia	7 - 8 minutes	3 - 5 minutes

In the field study, recovery times (extubation to head lift) following alfaxalone maintenance anesthesia averaged 15 minutes in cats that did not receive a preanesthetic, and 17 minutes in preanesthetized cats.

Inhalant anesthetic maintenance of general anesthesia in cats: Additional low doses of ALFAXAN MULTIDOSE, similar to a maintenance dose, may be required to facilitate the transition to inhalant maintenance anesthesia.

DOGS
Induction of general anesthesia in dogs: Induction dose guidelines are based on data from the field study (see EFFECTIVENESS) and range between 1.5 - 4.5 mg/kg for dogs that did not receive a preanesthetic, and between 0.2 - 3.5 mg/kg for dogs that received a preanesthetic. The alfaxalone induction dose in the field study was reduced by 23 - 50% depending on the combination of preanesthetics (dose sparing effect). Dose sparing of ALFAXAN MULTIDOSE will depend on the potency, dose, and time of administration of the various preanesthetics that are used prior to induction. To avoid anesthetic overdose, titrate the administration of ALFAXAN MULTIDOSE against the response of the patient. In the field study, the use of a preanesthetic appeared to decrease the occurrence of apnea following alfaxalone induction in dogs.

In dogs, ALFAXAN MULTIDOSE usually produces recumbence within 60 seconds after the start of injection, and permits intubation within 1 - 2 minutes, irrespective of preanesthetic. The duration of anesthesia from a single induction dose is approximately 5 - 10 minutes in the unpreanesthetized dog. If a preanesthetic is used, anesthetic duration may be longer, depending on the class and dose of preanesthetic. Individual anesthesia times vary.

Examples from the field study of average induction doses (and ranges) for dogs that received various preanesthetics are presented as dosing guidelines in the table. The table is for guidance only. Draw up the maximum expected target dose and administer to effect. The actual induction dose should be based on patient response.

Alfaxalone Induction Dose Guidelines: DOGS

Preanesthetic	Average alfaxalone induction dose and range (mg/kg)	Number of dogs
No preanesthetic	2.2 (1.5 - 4.5)	17
Benzodiazepine + opioid + acepromazine	1.7 (0.9 - 3.5)	39
Opioid + acepromazine	1.6 (0.6 - 3.5)	80
Alpha ₂ -agonist	1.1 (0.2 - 2)	9

Additional doses of ALFAXAN MULTIDOSE similar to those used for maintenance (1.2 - 2.2 mg/kg) may be administered to facilitate intubation.

Maintenance of general anesthesia in dogs: Following induction of anesthesia with ALFAXAN MULTIDOSE and intubation, anesthesia may be maintained using intermittent ALFAXAN MULTIDOSE intravenous boluses or an inhalant anesthetic agent. A maintenance bolus containing 1.2 - 1.4 mg/kg provides an additional 6 - 8 minutes anesthesia in preanesthetized dogs. A dose of 1.5 - 2.2 mg/kg provides an additional 6 - 8 minutes of anesthesia in unpreanesthetized dogs. Clinical response may vary, and is determined by the dose, rate of administration, and frequency of maintenance injections.

ALFAXAN MULTIDOSE maintenance dose sparing is greater in dogs that receive a preanesthetic. Examples from the field study of maintenance doses for preanesthetized and unpreanesthetized dogs are presented as guidelines in the table. Maintenance dose and frequency should be based on the response of the individual patient.

Alfaxalone Maintenance Dose Guidelines: DOGS

Dose and Duration	Preanesthetized dogs	Unpreanesthetized dogs
Maintenance anesthesia doses	1.2 - 1.4 mg/kg	1.5 - 2.2 mg/kg
Mean duration of anesthesia	6 - 8 minutes	6 - 8 minutes

In the field study, recovery times (extubation to head lift) following alfaxalone maintenance anesthesia averaged 22 minutes in dogs that did not receive a preanesthetic, and 15 minutes in preanesthetized dogs.

Inhalant anesthetic maintenance of general anesthesia in dogs: Additional low doses of ALFAXAN MULTIDOSE, similar to a maintenance dose, may be required to facilitate the transition to inhalant maintenance anesthesia.

DRUG INTERACTIONS
No specific preanesthetic is either indicated or contraindicated with ALFAXAN MULTIDOSE. The necessity for and choice of preanesthetic is left to the discretion of the veterinarian. Preanesthetic doses may be lower than the label directions for their use as a single medication. ALFAXAN MULTIDOSE is compatible with benzodiazepines, opioids, alpha₂-agonists, and phenothiazines as commonly used in surgical practice.

In the field study, alfaxalone was used safely in cats and dogs that received frequently used veterinary products, including antibiotics, anticholinergics, vaccines, steroids, and dewormers.

CONTRAINDICATIONS
ALFAXAN MULTIDOSE is contraindicated in cats and dogs with a known sensitivity to ALFAXAN MULTIDOSE or its components, or when general anesthesia and/or sedation are contraindicated.

WARNINGS
Animal safety: When using ALFAXAN MULTIDOSE, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.

Rapid bolus administration or anesthetic overdose may cause cardiorespiratory depression, including hypotension, apnea, hypoxia, or death. Arrhythmias may occur secondary to apnea and hypoxia. In cases of anesthetic overdose, stop ALFAXAN MULTIDOSE administration and administer treatment as indicated by the patient's clinical signs. Cardiovascular depression should be treated with plasma expanders, pressor agents, anti-arrhythmic agents or other techniques as appropriate for the treatments of the clinical signs.

Human safety: Not for human use. Keep out of the reach of children.

ALFAXAN MULTIDOSE should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting.

Exercise caution to avoid accidental self-injection. Overdose is likely to cause cardiorespiratory depression (such as hypotension, bradycardia and/or apnea). Remove the individual from the source of exposure and seek medical attention. Respiratory depression should be treated by artificial ventilation and oxygen.

Avoid contact of this product with skin, eyes, and clothes. In case of contact, eyes and skin should be liberally flushed with water for 15 minutes. Consult a physician if irritation persists. In the case of accidental human ingestion, seek medical advice immediately and show the package insert or the label to the physician.

Note to physician: This product contains an injectable anesthetic.

CONTACT INFORMATION: For a copy of the Safety Data Sheet or to report adverse reactions, call Zoetis Inc. at 1-888-963-8471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or at www.fda.gov/reportanimalae.

DRUG ABUSE AND DEPENDENCE
Controlled substance: ALFAXAN MULTIDOSE contains alfaxalone a neurosteroid anesthetic and a class IV controlled substance.

Abuse: Alfaxalone is a central nervous system depressant that acts on GABA receptor associated chloride channels, similar to the mechanism of action of Schedule IV sedatives such as benzodiazepines (diazepam and midazolam), barbiturates (phenobarbital and methohexital) and fospropofol. In a drug discrimination behavioral test in rats, the effects of alfaxalone were recognized as similar to those of midazolam. These biochemical and behavioral data suggest that alfaxalone has an abuse potential similar to other Schedule IV sedatives.

Physical dependence: There are no data that assess the ability of alfaxalone to induce physical dependence. However, alfaxalone has a mechanism of action similar to the benzodiazepines and can block the behavioral responses associated with precipitated benzodiazepine withdrawal. Therefore, it is likely that alfaxalone can also produce physical dependence and withdrawal signs similar to that produced by the benzodiazepines.

Psychological dependence: The ability of alfaxalone to produce psychological dependence is unknown because there are no data on the rewarding properties of the drug from animal self-administration studies or from human abuse potential studies.

PRECAUTIONS
Rapid arousal: Careful monitoring of the patient is necessary due to possibility of rapid arousal.

Preanesthesia: Benzodiazepines may be used safely prior to ALFAXAN MULTIDOSE in the presence of other preanesthetics (see DRUG INTERACTIONS). However, when a benzodiazepine was used as the sole preanesthetic, excitation occurred in some cats and dogs during ALFAXAN MULTIDOSE anesthesia and recovery.

Apnea: Apnea may occur following administration of an induction dose, a maintenance dose or a dose administered during the transition to inhalant maintenance anesthesia, especially with higher doses and rapid administration. Endotracheal intubation, oxygen supplementation, and intermittent positive pressure ventilation (IPPV) should be administered to treat apnea and associated hypoxemia.

Blood pressure: The myocardial depressive effects of ALFAXAN MULTIDOSE combined with the vasodilatory effects of inhalant anesthetics can be additive, resulting in hypotension. Preanesthetics may increase the anesthesia effect of ALFAXAN MULTIDOSE and result in more pronounced changes in systolic, diastolic, and mean arterial blood pressures. Transient hypertension may occur, possibly due to elevated sympathetic activity.

Body temperature: A decrease in body temperature occurs during ALFAXAN MULTIDOSE anesthesia unless an external heat source is provided. Supplemental heat should be provided to maintain acceptable core body temperature until full recovery.

Breeding animals: ALFAXAN MULTIDOSE has not been evaluated in pregnant, lactating, and breeding cats. Alfaxalone crosses the placenta, and as with other general anesthetic agents, the administration of ALFAXAN MULTIDOSE may be associated with neonatal depression.

Kittens and puppies: ALFAXAN MULTIDOSE has not been evaluated in cats less than 4 weeks of age or in dogs less than 10 weeks of age.

Compromised or debilitated cats and dogs: The administration of ALFAXAN MULTIDOSE to debilitated patients or patients with renal disease, hepatic disease, or cardiorespiratory disease has not been evaluated. Doses may need adjustment for geriatric or debilitated patients. Caution should be used in cats or dogs with cardiac, respiratory, renal or hepatic impairment, or in hypovolemic or debilitated cats and dogs, and geriatric animals.

Analgesia during anesthesia: Appropriate analgesia should be provided for painful procedures.

ADVERSE REACTIONS

Adverse Reactions in Cat Field Study	
Adverse Reaction	Number of Cats ^a = 207
Hypotension (≤90 mm Hg)	92
Tachycardia (≥180 bpm)	61
Apnea (≥30 seconds)	32 (of 202)
Hypertension (>165 mm Hg)	23
Bradypnea (RR <10 breaths/min)	16
Apnea (≥60 seconds)	12 (of 202)
Bradycardia (≤90 beats/min)	10
Hypothermia (<97 °F)	10
Hypoxia (SpO ₂ <85%)	4
Emesis	1
Unacceptable anesthesia quality	1
^a Each cat may have experienced more than one adverse reaction	

Additional adverse reactions for cats included vocalization, paddling, and muscle tremors. One cat that experienced tachycardia and hypoxia during anesthesia was euthanized 3 days later due to carcinoma involving the liver, pancreas and common bile duct. The relationship of the original tachycardia during anesthesia and the carcinoma is unknown.

Adverse Reactions in Dog Field Study	
Adverse Reaction	Number of Dogs ^a = 182
Bradypnea (RR <10 breaths/min)	89
Apnea (≥30 seconds)	55 (of 137)
Hypertension (>165 mm Hg)	54
Tachycardia (≥180 bpm)	49
Apnea (≥60 seconds)	34 (of 137)
Hypotension (≤70 mm Hg)	32
Hypothermia (<97 °F)	28
Bradycardia (≤70 beats/min)	24
Hypoxia (SpO ₂ <85%)	4
Lack of effectiveness	3
Unacceptable anesthesia quality	1
Emesis	1
^a Each dog may have experienced more than one adverse reaction	

Additional adverse reactions for dogs included vocalization, paddling, and muscle tremors. To report adverse reactions or to obtain a copy of the SDS for this product call 1-888-963-8471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>.

OVERDOSE

Rapid administration, accidental overdose, or relative overdose due to inadequate dose sparing of ALFAXAN MULTIDOSE in the presence of preanesthetics may cause cardiopulmonary depression. Respiratory arrest (apnea) may be observed. In cases of respiratory depression, stop drug administration, establish a patent airway, and initiate assisted or controlled ventilation with pure oxygen. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other techniques as appropriate for the observed abnormality.

CLINICAL PHARMACOLOGY

ALFAXAN MULTIDOSE is a reformulation of previously approved, single-use ALFAXAN (NADA 141-342) which contained no antimicrobial preservative. The bioequivalence of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE following administration of 5 mg/kg IV was demonstrated in a two sequence, two period crossover study in 24 cats (see EFFECTIVENESS). The bioequivalence of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE following administration of 3 mg/kg IV was demonstrated in a two sequence, two period crossover study in 24 dogs (see EFFECTIVENESS).

EFFECTIVENESS

Cat bioequivalence study: The bioequivalence of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE following administration of 5 mg/kg IV was demonstrated in a two sequence, two period crossover study in 24 cats. The two products were bioequivalent because the upper and lower bounds of the 90% confidence intervals for C_{max} and AUC_{last} of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE met the bioequivalence criteria of 80 - 125%.

Table 1. Summary of bioequivalence parameters following a single IV administration of 5 mg/kg in cats of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE:

Parameter	Product	Geo LSMean†	T/R*	Lower Bound‡	Upper Bound‡
C _{max} (µg/mL)	ALFAXAN (unpreserved)	8.45	0.97	91.58%	102.38%
	ALFAXAN MULTIDOSE	8.18			
AUC _{last} (min*µg/mL)	ALFAXAN (unpreserved)	186.07	0.98	93.11%	102.77%
	ALFAXAN MULTIDOSE	182.01			

*T/R = Test/Reference = ALFAXAN MULTIDOSE/ALFAXAN (unpreserved)
†Geometric means
‡Lower and upper 90% confidence bounds for the ratio of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE

Dog bioequivalence study: The bioequivalence of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE following administration of 3 mg/kg IV was demonstrated in a two sequence, two period crossover study in 24 dogs. The two products were bioequivalent, because the upper and lower bounds of the 90% confidence intervals for C_{max} and AUC_{last} of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE met the bioequivalence criteria of 80 - 125%.

Table 2. Summary of bioequivalence parameters following a single IV administration of 3 mg/kg in dogs of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE:

Parameter	Product	Geo LSMean†	T/R*	Lower Bound‡	Upper Bound‡
C _{max} (µg/mL)	ALFAXAN (unpreserved)	4.42	1.07	100.26%	114.57%
	ALFAXAN MULTIDOSE	4.74			
AUC _{last} (min*µg/mL)	ALFAXAN (unpreserved)	74.77	1.06	101.52%	109.72%
	ALFAXAN MULTIDOSE	78.92			

*T/R = Test/Reference = ALFAXAN MULTIDOSE/ALFAXAN (unpreserved)
†Geometric means
‡Lower and upper 90% confidence bounds for the ratio of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE

Cat field study: Two hundred and seven cats of 19 breeds, between the ages of 1 month to 17 years, weighing between 0.6 - 9 kg, were successfully anesthetized with alfaxalone (unpreserved) for various types of surgery or procedures requiring anesthesia. Induction doses ranged between 1 - 10.8 mg/kg for cats that received preanesthetics, and between 2.2 - 9.7 mg/kg for unpreanesthetized cats (see DOSAGE AND ADMINISTRATION for doses by preanesthetic treatment groups). For most cats, the alfaxalone induction dose was reduced (10 - 43%), depending on the combination of preanesthetics (dose sparing effect). One hundred and four cats were maintained using an inhalant anesthetic; 72 cats were maintained using between 1 to 5 alfaxalone boluses. Mean alfaxalone maintenance doses ranged between 1.1 - 1.3 mg/kg in preanesthetized cats and 1.4 - 1.5 in unpreanesthetized cats. Doses were given to effect and titrated against the response of the individual patient.

All cats in the field study were intubated and received supplemental oxygen. Apnea ≥30 seconds occurred in 28 (of 169) preanesthetized cats and 4 (of 33) unpreanesthetized cats after induction with alfaxalone. Apnea continued ≥60 seconds in 9 of the 28 apneic preanesthetized cats and 3 of the 4 apneic unpreanesthetized cats after induction with alfaxalone. Other adverse reactions included hypotension, tachycardia, hypertension, bradypnea, bradycardia, and hypothermia (see ADVERSE REACTIONS).

In the field study, recovery times (extubation to head lift) following alfaxalone maintenance anesthesia averaged 15 minutes in cats that did not receive a preanesthetic, and 17 minutes in preanesthetized cats. Average recovery times following the use of an inhalant anesthetic ranged between 1 - 95 minutes (mean 14 minutes).

Dog field study: One hundred eighty-two dogs of 54 breeds, between the ages of 3 months to 13 years, weighing between 2.4 and 41 kg, were successfully anesthetized with alfaxalone (unpreserved) for various types of surgery or procedures requiring anesthesia. Induction doses ranged between 0.2 - 3.5 mg/kg for preanesthetized dogs, and between 1.5 - 4.5 mg/kg for dogs that did not receive a preanesthetic (see DOSAGE AND ADMINISTRATION for doses by preanesthetic treatment groups). The alfaxalone induction dose in the field study was reduced by 23 - 50% depending on the combination of preanesthetics (dose sparing effect). One hundred and eighteen dogs were maintained using an inhalant anesthetic; 17 dogs were maintained using between 1 - 5 alfaxalone boluses. Alfaxalone maintenance doses ranged between 1.2 - 1.4 mg/kg in preanesthetized dogs and 1.5 - 2.2 in unpreanesthetized dogs. Doses were given to effect and titrated against the response of the individual patient.

All dogs in the field study were intubated and received supplemental oxygen. Following induction using alfaxalone, apnea ≥30 seconds occurred in 46 (of 123) preanesthetized dogs and 9 (of 17) unpreanesthetized dogs. Apnea continued for ≥60 seconds in 18 of the 46 apneic preanesthetized dogs and 8 of the 9 apneic unpreanesthetized dogs after induction with alfaxalone. The duration of apnea ranged between 38 seconds and 6 minutes, 47 seconds. Of the 17 dogs that received up to 5 alfaxalone maintenance boluses, 11 (64.7%) experienced 14 periods of apnea, averaging 2.6 minutes each. Other adverse reactions included bradypnea, hypotension, tachycardia, hypertension, hypothermia, and bradycardia (see ADVERSE REACTIONS).

ANIMAL SAFETY

Plasma concentrations of alfaxalone over time after IV administration of ALFAXAN (unpreserved) or ALFAXAN MULTIDOSE to cats and dogs were compared and found to be bioequivalent for AUC_{last} and C_{max} (see CLINICAL PHARMACOLOGY). Monitoring of physiological variables, evaluation of anesthetic induction, anesthetic effectiveness, anesthetic recovery, and anesthetic event times during the bioequivalence study showed that the two formulations result in similar pharmacodynamic effects. The demonstrated blood level bioequivalence supports the systemic safety of the ALFAXAN MULTIDOSE formulation.

Cat multiple dose safety study: In a multiple dose safety study, 5 groups of 6 healthy cats (half male, half female) were administered alfaxalone (unpreserved) at 0 (saline), 5, 15 and 25 mg/kg on days 0, 2 and 5, at 48 hour intervals. Variables included induction and recovery times, heart rate (HR), respiratory rate (RR), indirect blood pressure (BP), clinical pathology, and necropsy. Anesthetic and cardiorespiratory variables were collected prior to induction and at 10 minute intervals after each induction until recumbence. Electrocardiograms (ECG) were monitored at observation time points.

Recovery time increased with increasing dose. Increasing doses of alfaxalone resulted in decreases in heart rate, respiratory rate, and blood pressure within 15 minutes post-induction. The lowest RR (18 breaths per minute) seen at 15 and 25 mg/kg occurred at 50 and 5 minutes post-dose respectively. Cats in the 5 mg/kg dose group reached a minimum of 23 breaths per minute at 10 minutes post-dose. During the initial 5 minutes after induction, there was 1 episode of apnea at 5 mg/kg, 6 episodes of apnea at 15 mg/kg, and 3 episodes of apnea at 25 mg/kg. Decreases in mean hemoglobin saturation (SpO₂) were not dose related. The lowest mean hemoglobin concentration for cats in both the 5 and 15 mg/kg dose groups were approximately 88%. For cats that received 25 mg/kg, the lowest SpO₂ was 83%. Mean systolic and diastolic blood pressure decreased with increasing dose. No abnormal cardiac arrhythmias were noted during the study (ECG observed but not recorded). Clinical pathology abnormalities were not clinically significant for all groups. Abnormal necropsy and histopathology findings were associated with injection site trauma consistent with intravenous injection and repeat catheterization. No pain on injection was reported.

The most common adverse reactions were post-anesthetic coughing, fluid in the endotracheal tube, and increased airway sounds. One death occurred in the 25 mg/kg group due to complications associated with a traumatic fall following extubation.

Cat preanesthetic compatibility study: Thirty healthy cats (15 female and 15 male cats) were allocated to each of 5 preanesthetic treatment groups. Alfaxalone dose sparing and the cardiovascular and respiratory interaction of alfaxalone when administered following intramuscular preanesthetic administration of acepromazine, medetomidine, midazolam, butorphanol, or saline, were evaluated. No procedures were performed; no cat received maintenance anesthesia.

Preanesthetic, preanesthetic dose, alfaxalone dose, and duration of anesthesia

Preanesthetic (IM)	Preanesthetic Dose	Alfaxalone IV Induction Dose (mg/kg)	Average Duration of Anesthesia (min)
medetomidine	100 mcg/kg	2.2	98.2
acepromazine	1.1 mg/kg	2.7	36.3
butorphanol	0.4 mg/kg	2.8	26.5
0.9% saline	0 mg/kg	3	26.1
midazolam	0.1 mg/kg	3.3	16.7

Cats given midazolam as the sole preanesthetic required more alfaxalone than the saline group. Durations of recovery increased with the duration of anesthesia. Physiologic variables (HR, RR, BP, SpO₂) remained satisfactory during anesthesia and reflected the effects primarily of the associated preanesthetic. Transient cardiac arrhythmias were noted during alfaxalone anesthesia in several cats. Three cats preanesthetized with medetomidine experienced sinus arrhythmias (1 prior to alfaxalone) and 3 were bradycardic (HR <110 bpm). Two cats that received midazolam preanesthesia showed isolated ventricular premature contractions (VPC; 1 prior to alfaxalone).

The quality of anesthesia based on overall anesthetic scores was acceptable for all groups. However, the quality of midazolam preanesthesia, when used alone prior to alfaxalone anesthesia, was less satisfactory compared with other preanesthetics.

Cat tolerance safety study: Eight adult, healthy cats (4 male and 4 female) received 0 (saline), 5, 15, and 50 mg/kg of alfaxalone (unpreserved) over 2 days in a dose escalation design, with at least 3 hours between doses.

Decreases in HR, RR, decreases in PaO₂, and increases in PaCO₂ were related to dose. All cardiopulmonary variables returned to baseline values by 15 minutes (5 mg/kg), 30 minutes (15 mg/kg) and 1 hour (50 mg/kg) after alfaxalone administration. The 50 mg/kg dose produced marked cardiovascular depression lasting from 10 to 30 minutes. Five of seven cats dosed at 50 mg/kg were euthanized due to prolonged hypoxia after 5 hours of anesthesia.

Apnea occurred at all doses. Respiratory depression and apnea (duration averaging 21 seconds, 63 seconds and 28 minutes) were observed at the 5, 15 and 50 mg/kg doses, respectively. The duration of apnea generally increased with the alfaxalone dose, occurring more often and for longer duration at 15 and 50 mg/kg. One cat experienced apnea lasting 3 minutes at 5 mg/kg. Tracheal intubation and administration of 100% oxygen and manual artificial ventilation were needed to raise arterial PaO₂ from < 60 mm Hg to > 80 mm Hg. Five cats received oxygen at 5 mg/kg, 7 received oxygen at 15 mg/kg, and all cats required oxygen at 50 mg/kg. Other adverse reactions at 5 mg/kg included 1 cat with cyanotic mucous membranes, and 1 cat with fluid in the endotracheal tube.

Duration of anesthesia increased with higher doses, lasting 26, 83, and 126 minutes after administration of 5, 15, and 50 mg/kg, respectively. Average quality scores (1, 2 or 3 - with 1 being the best) for induction and anesthesia were 1 for cats that received the 5 or 15 mg/kg doses. Average quality scores for recovery were 1 and 1.1 for the 5 and 15 mg/kg groups, respectively.

Dog multiple dose safety study: In a multiple dose safety study, 4 groups of 6 healthy Beagle dogs (3 male, 3 female) were administered alfaxalone (unpreserved) at 0 (saline), 2, 6, and 10 mg/kg, 3 times at 48 hour intervals. Variables included induction and recovery times, HR, RR, indirect BP, clinical pathology, urinalysis, and necropsy. Anesthetic and cardiorespiratory variables were collected prior to induction and at 10 minute intervals after each induction until recumbency. Health observations, clinical pathology, and urinalysis variables were collected during the study on non-treatment days.

Induction times decreased and recovery times increased with relation to the anesthetic dose. Body temperature decreased in proportion to the dose and the length of anesthesia. The minimum rectal temperature recorded was 98.3°F. There was a dose related decrease in SpO₂, respiratory rate, and blood pressures. Mean heart rates increased with the increase in alfaxalone dosage. Mean heart rates also increased when compared to the pre-dose heart rate at the 10-minute time point for all groups. Heart rates returned to pre-dose rates or below at the 20 minute time points for the 2 mg/kg and 6 mg/kg groups, and at the 30 minute time point for the 10 mg/kg group. There was a decrease in the mean respiratory rates for all treatment groups when compared to the pre-dose rate, lowest at the 10 minutes time point. Mean systolic BP decreased and was lowest in all groups at the 10 minute time point for the 2 mg/kg dogs, and at the 20 minute time point for the 6 mg/kg and 10 mg/kg dogs. Similar trends were recorded for diastolic BP and MAP. Clinical pathology abnormalities were not clinically significant in all groups; abnormal necropsy and histopathology findings were associated with injection site trauma consistent with intravenous injection and repeat catheterization. No pain on injection was reported. No abnormal cardiac arrhythmias were noted during the study (ECG observed but not recorded).

Dog preanesthetic compatibility study: Forty eight healthy Beagle dogs (24 males, 24 females) were enrolled with 3 females and 3 males allocated to each of 8 preanesthetic groups (0.9% saline, medetomidine 40 µg/kg, medetomidine 4 µg/kg, acepromazine 1.1 mg/kg, acepromazine 0.2 mg/kg, acepromazine 0.05 mg/kg, butorphanol 0.2 mg/kg, and midazolam 0.2 mg/kg). All treatment groups received a maximum induction dose of 2 mg/kg of alfaxalone (to achieve endotracheal intubation) in conjunction with an intravenous dose of differing preanesthetic according to treatment group. No procedure was performed. Data were collected on each dog for the quality of anesthesia, as well as cardiovascular and respiratory parameters. Data for the cardiovascular and respiratory variables were collected between preanesthetic administration until recovery at intervals of -60, -5, 5, 10, 15, and 20 minutes and every 10 minutes thereafter.

Dose sparing occurred with acepromazine, medetomidine, and butorphanol. Dogs administered midazolam required an increase in dose compared to the saline group. The high medetomidine and 1.1 mg/kg acepromazine groups had the largest dose sparing effect on alfaxalone. The 0.2 mg/kg and 1.1 mg/kg acepromazine, low dose medetomidine, midazolam, and butorphanol groups had mean durations of anesthesia between 7:58 and 10:17 min/sec. The high medetomidine group had a prolonged mean duration of anesthesia at 1:10:08 (hr/min/sec). Duration of recovery increased with the duration of anesthesia. Midazolam treated dogs had the least satisfactory recovery scores.

No dog experienced hypotension. Mean heart rates decreased compared to baseline values. Dogs in the high medetomidine group experienced bradycardia through the end of anesthesia. Heart rates for the saline, 0.05 mg/kg acepromazine, and midazolam groups increased between the -5 minutes and 5-minute time points. The midazolam group experienced mean heart rates of 170 - 175 at the 5 - 10 minute time points. Dogs in the 0.2 mg/kg and 1.1 mg/kg acepromazine group, and butorphanol group had stable heart rates from baseline, premedication, and through anesthesia. Electrocardiogram recordings were evaluated by the study investigator, and no abnormal findings were noted. Blood pressures were obtained by an indirect method and remained normal in all groups throughout anesthesia. Respiratory rates decreased in the high and low medetomidine groups after premedication (-5 minutes) and again after alfaxalone administration (5 minutes). Decreases for the other groups occurred after alfaxalone administration, and had not returned to baseline values at the last recorded time point. No apnea was observed.

Dog tolerance safety study: Eight dogs (4 male, 4 female) each received 0 (0.9% saline), 2, 6, and 20 mg/kg of alfaxalone (unpreserved) in sequence, with a 3 hour washout period between doses. There were no unscheduled deaths during the study. Necropsy and histopathology were not conducted. Alfaxalone produced dose related decreases in cardiovascular, respiratory, pH, and blood gas values, and dose related increases for duration of anesthesia, time to extubation, and time to sternal recumbency. There were no ECG abnormalities reported during the study. Observations during anesthesia included forelimb rigidity and shivering/shaking during recovery, paddling, excitement during recovery, inability to intubate (1x).

Apnea occurred in a dose dependent manner, and all dogs required oxygen supplementation and positive pressure ventilation after administration of the 20 mg/kg dose. One dog experienced apnea after administration of the 2 mg/kg dose, and 6 dogs experienced apnea after the 6 mg/kg dose. These dogs did not require oxygen supplementation. The mean duration of apnea also increased in a dose related manner. Decreases in respiratory rate were most profound at 1 through 10 minutes in the 6 mg/kg, and 1 through 30 minutes in the 20 mg/kg group. Tidal volume and minute volume decreased in a dose dependent manner, along with the respiratory rate.

Blood pressures were obtained from an arterial catheter. At all doses, there was an increase in the mean heart rate, compared to baseline values. At the 20 mg/kg dose, the heart rate returned to near baseline values between the 5 and 15 minute time points. At 20 mg/kg, the heart rates were tachycardic (means 155 - 168 bpm); at the 2 mg/kg and 6 mg/kg doses the heart rates were elevated (means 143-150 bpm). At the 2 mg/kg and 6 mg/kg doses, the MAP and systolic BP increased compared to baseline, and at the 20 mg/kg dose, the MAP and systolic BP decreased compared to baseline. These changes occurred at 1 and 5 minutes at the 2 mg/kg dose, and at 1 minute for the 6 mg/kg dose. The mean MAP and systolic BP returned to baseline values by the end of anesthesia. Cardiac output (CO) and central venous pressure (CVP) were lowest in the 20 mg/kg group at 5 and 30 minutes.

Dog cesarean section safety study: Forty-eight female dogs received alfaxalone (unpreserved) for induction prior to cesarean section, and were maintained using isoflurane. The average induction dose of alfaxalone was 1.9 mg/kg. Immediate, transient, post-induction apnea occurred in 15% of cases. Cardiovascular and respiratory parameters were well maintained during induction, maintenance and recovery, and anesthesia quality was scored as good during all phases. Puppy vigor scores were rated as very good for withdrawal reflex, sucking reflex, anogenital reflex, and flexion reflex. Puppy survival rate was 96.2% at 24 hours after birth.

STORAGE INFORMATION: Store at controlled room temperature 20°C - 25°C (68° to 77°F) with excursions between 15° and 30°C (59° and 86°F). ALFAXAN MULTIDOSE contains preservatives. The product can be used for 56 days after broaching the vial. Any unused ALFAXAN MULTIDOSE remaining after 56 days should be discarded.

HOW SUPPLIED: ALFAXAN MULTIDOSE is supplied in 10 and 20 mL multiple-dose vials containing 10 mg alfaxalone per mL.

ALFAXAN is a registered trademark of Jurox Pty Ltd.

Approved by FDA under NADA # 141-342

Manufactured in Australia by Jurox Pty Ltd.

Distributed by: **zoetis**

Zoetis Inc.
Kalamazoo, MI 49007

Alfaxan® Multidose IDX

(alfaxalone) 10 mg/mL Injectable Solution

For use as an injectable sedative and anesthetic in multiple non food-producing minor species.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
LEGAL STATUS: In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. **THIS PRODUCT IS INDEXED—MF 900-031. EXTRA-LABEL USE IS PROHIBITED.**
This product is not to be used in animals for use as food for humans or food-producing animals.

DESCRIPTION

ALFAXAN MULTIDOSE IDX contains alfaxalone, a neuroactive steroid molecule with properties of a general anesthetic. Alfaxalone is chemically described as 3- α -hydroxy-5- α -pregnane-11, 20-dione, and has a molecular weight of 332.5. The primary mechanism for the anesthetic action of alfaxalone is modulation of neuronal cell membrane chloride ion transport, induced by binding of alfaxalone to GABA_A (gamma-aminobutyric acid) cell surface receptors. **This product contains the following preservatives: chlorocresol (0.1% w/v), benzethonium chloride (0.02% w/v) and ethanol (15% w/v).**

INDICATIONS

ALFAXAN MULTIDOSE IDX is indicated as a sedative and anesthetic in multiple minor species*. More specifically, ALFAXAN MULTIDOSE IDX is indicated for the following:

- For sedation and anesthesia in captive reptiles, excluding any food-producing species**
- For sedation and anesthesia in captive amphibians, excluding any food-producing species**
- For sedation and anesthesia in ornamental fish, including species used in research such as the zebrafish
- For sedation and anesthesia in captive species and pet birds in the orders Psittaciformes, Passeriformes, and Columbiformes, excluding any food-producing species**
- For sedation and anesthesia in non-human primates
- For sedation and anesthesia in captive rodents
- For sedation and anesthesia in captive mustelids
- For sedation and anesthesia in captive marsupials
- For induction of anesthesia and immobilization in captive minor species ungulates, excluding any food-producing species**

Use only when there is reasonable certainty that the treated animal will not be consumed by humans or food-producing animals.

* The term "minor species" means animals other than humans that are not major species. "Major species" means cattle, horses, swine, chickens, turkeys, dogs and cats.
** As used on this label, a "food-producing minor species" is considered to be a minor species of which some members are bred, cultured, farmed, ranched, hunted, caught, trapped or otherwise harvested for the purpose of having the animals or edible products of the animals commercially distributed for consumption by humans or food-producing animals in the United States.

DOSAGE AND ADMINISTRATION

When administering ALFAXAN MULTIDOSE IDX by intravenous injection administer slowly to effect, titrating administration against the response of the patient. Rapid administration of ALFAXAN MULTIDOSE IDX may be associated with an increased incidence of cardiorespiratory depression or apnea. The use of preanesthetics may reduce the ALFAXAN MULTIDOSE IDX induction dose. The choice and the amount of phenothiazine, alpha-2 adrenoceptor agonist, benzodiazepine or opioid will influence the response of the patient to an induction dose of ALFAXAN MULTIDOSE IDX.

When using ALFAXAN MULTIDOSE IDX, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.

ALFAXAN MULTIDOSE IDX contains preservatives. Use within 56 days of first puncture. Any unused ALFAXAN MULTIDOSE IDX remaining after 56 days should be discarded.

The following tables outline the dosage and administration of ALFAXAN MULTIDOSE IDX for the indicated species by major group. The doses are representative of doses published in the literature. Veterinarians are advised to consult the published literature before use of the product (see List of References at end of product insert).

REPTILES

Lizards

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Blotched Bluetongue Lizard	9 mg/kg; IV	None	Ventral coccygeal vein; anesthesia not achieved in all cases		1
Eastern Bluetongue Lizard					1
Coastal Bearded Dragon					1
Inland Bearded Dragon					1
Gippsland Water Dragon					1
Green Iguana	20 mg/kg; IM	None	Anesthesia		2
	5 mg/kg; IV	None	Anesthesia		3
Veiled Chameleon	3 mg/kg; IV	None	Ventral coccygeal vein; anesthesia		4
Leopard Gecko	15 mg/kg; SC	Midazolam 1 mg/kg; SC	Deep sedation		5
	5 mg/kg; IV	None	Anesthesia		6
Perentie Monitor	5 mg/kg; IV	None	Anesthesia		7
Bearded Dragon	5 mg/kg; IV	Meloxicam 1 mg/kg + Butorphanol 2 mg/kg; IM or Tramadol 10 mg/kg; IM	Anesthesia		8
	12 mg/kg; IV	None	Anesthesia		9

Snakes

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Red-bellied Black	9 mg/kg; IV	None	Ventral coccygeal vein; anesthesia		1
Lowland Copperhead					1
Eastern Tiger					1
Coastal Carpet Python					1
Black Headed Python					1
Ball Python	20 mg/kg; IM	None	Anesthesia (cranial injection site required)		10
Garter Snake	30 mg/kg; Intracoelomic	None	Loss of righting reflex		11

Turtles and Tortoises

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Red Eared Slider Turtle	5 mg/kg; IV	None	Anesthesia		12
	10-20 mg/kg; IM	None	Lower environmental temperatures and or body temperature prolonged anesthesia		13
	3, 5 and 10 mg/kg; IV	None	Anesthesia	10 mg/kg dose produced apnea	14
Loggerhead Sea Turtle	5 mg/kg; IV	Meloxicam 1 mg/kg; IM and Butorphanol 2 mg/kg; IM	Anesthesia		12
Hartmann's Tortoise					12
Spur-Thighed Tortoise					12
Marginated Tortoise					12
Russian Tortoise	5 mg/kg; IV	Meloxicam 1 mg/kg; IM and Butorphanol 2 mg/kg; IM	Anesthesia		12
	10 mg/kg; IM	Medetomidine 0.05 mg/kg; IM	Moderate/deep sedation; minimal analgesia	Bradycardia was observed with this combination of drugs	15
	20 mg/kg; IM	Medetomidine 0.1 mg/kg; IM	Deep sedation/anesthesia; variable analgesia		
Red Footed Tortoise	10 mg/kg; IM	Midazolam 1 mg/kg and Hydromorphone 0.5 mg/kg; IM (front legs)	Anesthesia		16
Pond Sklders	10 mg/kg; IV	None	Via subcarapacial vein; Anesthesia		17
Spur-Thighed Tortoise	10 mg/kg; IV	Morphine 1.5 mg/kg and Meloxicam 0.2 mg/kg; SC	Via jugular vein; Anesthesia		18

AMPHIBIANS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	General Comments	Precautions/ Adverse Reactions	Reference Number
Oriental Fire Bellied Toad	30 mg/L H ₂ O*; immersion	Butorphanol 25 mg/L H ₂ O*; immersion (butorphanol combined with ALFAXAN MULTIDOSE IDX in same bath)	Surgical anesthesia was observed in both treatment groups. The baths were adjusted to pH 7-7.0 with sodium bicarbonate, 8.4%. One third of the toad's surface area was immersed to avoid drowning.		19
	30 mg/L H ₂ O*; immersion	Morphine 50 mg/L H ₂ O*; immersion (morphine combined with ALFAXAN MULTIDOSE IDX in same bath)			
Australian Frog	20-30 mg/kg; IM	None	Anesthesia		20
Axolotl	5 mg/L H ₂ O*; first immersion then continuous irrigation of the gills and skin after the axolotl was removed from the bath	None	The anesthetic bath was prepared to pH 6.5. Additional 30 μ L drops of stock ALFAXAN MULTIDOSE IDX were applied to gills when required. Mild sedation was produced with initial immersion and anesthesia produced with subsequent drops.		21

* Anesthetic baths were prepared using dechlorinated mineral water at room temperature

FISH

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Goldfish	0.5, 2, 5 & 7.5 mg/L H ₂ O*; immersion	None	Sedation at 0.5 and 2 mg/L. Anesthesia at 5 and 7.5 mg/L		22
	5 mg/L H ₂ O; immersion followed by continuous gill irrigation with 5 mg/L H ₂ O	None	Anesthesia		23
Koi	10 mg/L H ₂ O*; immersion followed by continuous gill irrigation with 1 or 2.5 mg/L H ₂ O	None	All fish anesthetized. Opercular movement observed in 4 of 6 fish at 2.5 mg/L H ₂ O		24
Oscar Fish	5 mg/L H ₂ O*; immersion	None	Anesthesia		25
Zebrafish	10 mg/L H ₂ O*; immersion	None	Anesthesia		26

^ Water tanks at temperature (72-77°F); pH (6.8-7.2); osmolality (38-45 mOsm/L)
Dechlorinated water at temperature (63-65°F); pH (6.9-7.6), total ammonia (0.0-0.25 mg/L); nitrate (0.0-5.0 mg/L)
@ Dechlorinated water at temperature 77 °F
\$ Water tank at temperature 80°F; pH 7.9

BIRDS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Budgerigar	10 mg/kg; IM	None	Sedation		27
	15 mg/kg; IM	None	Sedation		28
Bengalese Finch	10, 30 & 50 mg/kg; SC	Midazolam 0.7 mg/kg <i>or</i> Butorphanol 1 mg/kg SC combined with 30 mg/kg ALFAXAN MULTIDOSE IDX; SC	Dose dependent response in duration of recumbency. Addition of midazolam or butorphanol produced a further increase in the duration of anesthesia.		29
Flamingo	2 mg/kg; IV	Isolurane used for maintenance of anesthesia	Induction of anesthesia		30
Mute Swan	10 mg/kg; IV	Isolurane used for maintenance of anesthesia	Induction of anesthesia	Induction apnea (<1 breath/30 sec) was observed in 12/27 swans or 44%	31

NON-HUMAN PRIMATES

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Ring Tailed Lemur	Initially 0.5 mg/kg; IV	Dexmedetomidine 0.015 mg/kg, Butorphanol 0.2 mg/kg, Midazolam 0.2 mg/kg; all IM	Bolused to effect until endotracheal intubation completed		32
Macaque	10 mg/kg; IM	Diazepam 3 mg/kg and Atropine 0.2 mg/kg; IM	Supplemental doses of 5 mg/kg Alfaxan Multidose IDX administered IV to maintain anesthesia		33
Common Marmoset	12 mg/kg; IM	None	Sedation		34
	15 mg/kg; IM	None	Anesthesia		35
	12-18 mg/kg; IM	Diazepam 0.25 mg/kg; IM	Anesthesia		36
	18.5 mg/kg; IM	None	Anesthesia		37
	10.6 \pm 1.6 mg/kg; IM	None	3.2 \pm 1.2 mg/kg administered IV after the IM dose		38

RODENTS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Mice	15-20 mg/kg; IV	None	Anesthesia maintained with 0.25-0.75 mg/kg/min; IV		39
	80 mg/kg; IP	Xylazine 10 mg/kg; IP	Longer sleep times observed in female vs. male mice with ALFAXAN MULTIDOSE IDX \pm xylazine IP	Mild seizure-like activity appeared in some mice	40
Mice	60 mg/kg; SC	Medetomidine 0.3 mg/kg and Butorphanol 5 mg/kg; SC	Anesthesia	%Medetomidine should be used with caution in male mice (obstructive uropathy)	41
Rats	10-12 mg/kg; IV	None	Anesthesia maintained with 0.25-0.75 mg/kg/min; IV		39
	2-5 mg/kg; IV	None	Anesthesia produced IV	A 30% failure rate for anesthesia observed IP.	42
	20 mg/kg; IP				
	30 mg/kg/hr; IV				43
	25 mg/kg; IP (females)	Dexmedetomidine 0.05 mg/kg; IP <i>or</i> Dexmedetomidine 0.05 mg/kg + Fentanyl 0.1 mg/kg; IP	Anesthesia. Males rats appeared to require more ALFAXAN MULTIDOSE IDX than female rats to produce a similar duration of anesthesia		44
	1.7 mg/kg/min for 2.5 min IV (induction of anesthesia)	None	Anesthesia maintained at 0.75 mg/kg/min; IV		45
Guinea Pig	5 mg/kg; IM	None	Sedation		46
	20 mg/kg; SC	+/- Dexmedetomidine 0.25 mg/kg; SC and Buprenorphine 0.05 mg/kg; SC	Sedation		47

% Wells S, et al. Urethral obstruction by seminal coagulum is associated with medetomidine-ketamine anesthesia in male mice on C57BL/6J and mixed genetic backgrounds. Am Assoc Lab Anim Sci 2009;48(3):296-299.

FERRETS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Ferret	6 mg/kg; IM	Butorphanol 0.1 mg/kg and midazolam 1 mg/kg; IM as premedication	Anesthesia maintained with 3 – 15 mg/kg/hr ALFAXAN MULTIDOSE IDX		48
	5 mg/kg; IV	Dexmedetomidine 0.05 mg/kg; SC as premedication	Anesthesia		49
	5 mg/kg; IV	None	Anesthesia		50
	2.5 mg/kg; IV	Medetomidine 0.02 mg/kg; IM as premedication			

MARSUPIALS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Koala	3 mg/kg; IM	None	Anesthesia maintained with isoflurane in oxygen		51, 52, 53, 54, 55, 56
	2 mg/kg; IM	None	Anesthesia maintained with isoflurane in oxygen		57
	1.5 mg/kg; IV	None	Anesthesia		51
Wallaby	5 mg/kg; IM	Medetomidine 0.1 mg/kg; IM	Anesthesia. Drugs administered together in a dart.		58
Kangaroos and Wallabies	5–8 mg/kg; IM 1.5–3 mg/kg; IV	None	Anesthesia		51
Possums and Gliders	5–8 mg/kg; IM 5 mg/kg; IV	None	Rapid and short duration of anesthesia produced.		51
Wombats	3–5 mg/kg; IM	None	Anesthesia		51

MINOR SPECIES UNGULATES

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Alpaca	2.1 mg/kg; IV	None	Anesthesia achieved but poor quality of recovery observed.	Premedication is indicated prior to induction of anesthesia. Premedication will aid in induction of anesthesia and improve the quality of recovery in short procedures.	59

DRUG INTERACTIONS

No specific preanesthetic is either indicated or contraindicated with ALFAXAN MULTIDOSE IDX. The necessity for and choice of preanesthetic is left to the discretion of the veterinarian. Preanesthetic doses may be lower than the label directions for their use as a single medication. ALFAXAN MULTIDOSE IDX is compatible with benzodiazepines, opioids, alpha-agonists, and phenothiazines as commonly used in surgical practice.

CONTRAINDICATIONS

ALFAXAN MULTIDOSE IDX is contraindicated in animals with a known sensitivity to ALFAXAN MULTIDOSE IDX or its components, or when general anesthesia and/or sedation are contraindicated. Do not use in any minor species animal that may become eligible for consumption by humans or food-producing animals.

WARNINGS

Animal Safety: Rapid bolus administration or anesthetic overdose may cause cardiorespiratory depression, including hypotension, apnea, hypoxia, or death. Arrhythmias may occur secondary to apnea and hypoxia. In cases of anesthetic overdose, stop ALFAXAN MULTIDOSE IDX administration and administer treatment as indicated by the patient's clinical signs. Cardiovascular depression should be treated with plasma expanders, pressor agents, anti-arrhythmic agents or other techniques as appropriate for the treatments of the clinical signs.

Human Safety: Not for human use. Keep out of the reach of children.

ALFAXAN MULTIDOSE IDX should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting.

Exercise caution to avoid accidental self-injection. Overdose is likely to cause cardiorespiratory depression (such as hypotension, bradycardia and/or apnea). Remove the individual from the source of exposure and seek medical attention. Respiratory depression should be treated by artificial ventilation and oxygen. Avoid contact of this product with skin, eyes, and clothes. In case of contact, eyes and skin should be liberally flushed with water for 15 minutes. Consult a physician if irritation persists. In the case of accidental human ingestion, seek medical advice immediately and show the package insert or the label to the physician.

The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report adverse reactions in users or to obtain a copy of the SDS for this product call 1-888-963-8471.

Note to physician: This product contains an injectable anesthetic.

DRUG ABUSE AND DEPENDENCE

Controlled substance: ALFAXAN MULTIDOSE IDX contains alfaxalone, a neurosteroid anesthetic and a class IV controlled substance.

Abuse: Alfaxalone is a central nervous system depressant that acts on GABA receptor associated chloride channels, similar to the mechanism of action of Schedule IV sedatives such as benzodiazepines (diazepam and midazolam), barbiturates (phenobarbital and methohexital) and fospropofol. In a drug discrimination behavioral test in rats, the effects of alfaxalone were recognized as similar to those of midazolam. These biochemical and behavioral data suggest that alfaxalone has an abuse potential similar to other Schedule IV sedatives.

Physical dependence: There are no data that assess the ability of alfaxalone to induce physical dependence. However, alfaxalone has a mechanism of action similar to the benzodiazepines and can block the behavioral responses associated with precipitated benzodiazepine withdrawal. Therefore, it is likely that alfaxalone can also produce physical dependence and withdrawal signs similar to that produced by the benzodiazepines

Psychological dependence: The ability of alfaxalone to produce psychological dependence is unknown because there are no data on the rewarding properties of the drug from animal self-administration studies or from human abuse potential studies.

PRECAUTIONS

Analgesia during anesthesia: ALFAXAN MULTIDOSE IDX is not an analgesic and appropriate analgesia should be provided to the patient for painful procedures.

Rapid arousal: Careful monitoring of the patient is necessary due to possibility of rapid arousal.

Apnea: Apnea may occur following IV administration of an induction dose, maintenance dose or a dose administered during transition to inhalant maintenance anesthesia of ALFAXAN MULTIDOSE IDX, especially with higher doses and rapid administration. Endotracheal intubation, oxygen supplementation and intermittent positive pressure ventilation (IPPV) should be administered to treat apnea and associated hypoxemia in the appropriate species.

Blood Pressure: ALFAXAN MULTIDOSE IDX can exacerbate the myocardial depressive and vasodilatory effects of inhalant anesthetics resulting in hypotension. Preanesthetics can potentiate the effect of ALFAXAN MULTIDOSE IDX resulting in more pronounced changes in blood pressure. Transient hypertension has also been observed with ALFAXAN MULTIDOSE IDX administration, possibly due to elevated sympathetic activity in the patient. It is prudent to monitor blood pressure whenever possible.

Body temperature: Steps should be taken to maintain the normal physiological temperature of the patient during anesthesia. Supplemental heat, appropriate for the species, should be provided to maintain acceptable core body temperature until full recovery.

Breeding animals: Alfaxalone crosses the placenta, and as with other general anesthetic agents, the administration of ALFAXAN MULTIDOSE IDX may be associated with neonatal depression.

Compromised or debilitated animals: Caution should be used in animals with cardiac, respiratory, renal or hepatic impairment, or in hypovolemic or debilitated animals and geriatric animals.

ADVERSE REACTIONS

Specific adverse reactions described in the referenced literature are listed in the Dosage and Administration section of the product insert.

CONTACT INFORMATION

For a copy of the Safety Data Sheet or to report adverse reactions, call Zoetis Inc. at 1-888-963-8471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VEIS or at www.fda.gov/reportanimalae.

OVERDOSE

Rapid administration, accidental overdose, or relative overdose due to inadequate dose sparing of ALFAXAN MULTIDOSE IDX in the presence of preanesthetics may cause cardiopulmonary depression. Respiratory arrest (apnea) may be observed. In cases of respiratory depression, stop drug administration, establish a patent airway, and initiate assisted or controlled ventilation with pure oxygen. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other techniques as appropriate for the observed abnormality.

STORAGE INFORMATION: Store at controlled room temperature 20°C – 25°C (68° to 77°F) with excursions between 15° and 30°C (59° and 86°F). ALFAXAN MULTIDOSE IDX contains preservatives. The product can be used for 56 days after breaching the vial. Any unused ALFAXAN MULTIDOSE IDX remaining after 56 days should be discarded.

HOW SUPPLIED: ALFAXAN MULTIDOSE IDX is supplied in 10 mL and 20 mL multiple-dose vials containing 10 mg alfaxalone per mL.

ALFAXAN is a registered trademark of Jurox Pty Ltd.

Manufactured in Australia by Jurox Pty Ltd.

Distributed by:

zoetis

Zoetis Inc.
Kalamazoo, MI 49007

LIST OF REFERENCES

- Scheelings TF, Baker RT, Hammersley G, Hollis K, Elton I, Holz P. A preliminary investigation into the chemical restraint of selected Australian squamate species with Alfalone. *J Herpetol Med Surg* 2011;2(2-3): 63-77.
- Bertelsen MF, Sauer CD. Alfaxalone anesthesia in the green iguana (*Iguana iguana*). *Vet Anaesth Analg* 2011;38(5):461-6.
- Knotek Z, Hrdá A, Knotkova Z, Trnková S, Babák V. Alfaxalone anesthesia in the green iguana (*Iguana iguana*). *ACTA VET BRNO* 2013;82:109–114.
- Rowland MN. Fibrosing myopathy of the temporal muscles causing lockjaw in a veiled chameleon (*Chamaeleo calyptratus*). *Vet Rec* 2011;169:527b.
- Doss GA, Fink DM, Slidky KK, Mans C. Comparison of subcutaneous dexmedetomidine-midazolam versus alfaxalone-midazolam sedation in leopard geckos (*Eublepharis macularius*). *Vet Anaesth Analg* 2017;44(5):1173-1183.
- Morici M, DiGiuseppe M, Spadola F, Oliveri M, Knotkova Z, Knotek Z. Intravenous alfaxalone anesthesia in leopard geckos (*Eublepharis macularius*). *J Exot Pet Med* 2018;27(3):11-14.
- Hoffman EM, Garrett K, Doneley RJT. Pneumocoelom causing choanal prolapse in a perentie monitor (*Varanus giganteus*). *Australian Veterinary Practitioner* 2017;47(4):117-120.
- Knotek Z. Induction to inhalation anaesthesia in agamid lizards with alfaxalone. *Veterinari Medicina* 2017;62(01):41–43.
- Perrin KL, Bertelsen MF. Intravenous alfaxalone and propofol anesthesia in the bearded dragon (*Pogona vitticeps*). *Herpetol Med Surg* 2017;27(3-4):123-126.
- James LE, Williams CJ, Bertelsen MF, Wang T. Anesthetic induction with alfaxalone in the ball python (*Python regius*): dose response and effect of injection site. *Vet Anaesth Analg* 2018;45(3):329-337.
- Strahl-Heddreth D, Dark-Price SC, Keating SCJ, Graham LF, Chinnadurai SK, Schaeffer. Effect of intraoelomic administration of alfaxalone on the righting reflex and tactile stimulus response of common garter snakes (*Thamnophis sirtalis*). *Am J Vet Res* 2019;80(2):144-151.
- Knotek Z. Alfaxalone as an induction agent for anesthesia in terrapins and tortoises. *Vet Rec* 2014;175(13):327.
- Kischinsky M, Duse A, Wang T, Bertelsen MF. Intramuscular administration of alfaxalone in red-eared sliders (*Trachemys scripta elegans*)-effects of dose and body temperature. *Vet Anaesth Analg* 2013;40(1):3-20.
- Phillips BE, Posner LP, Lewbart GA, Christiansen EF, Harms CA. Effects of alfaxalone administered intravenously to healthy yearling loggerhead sea turtles (*Caretta caretta*) at three different doses. *J Am Vet Med Assoc* 2017;250(8):909-917.
- Hansen LL, Bertelsen MF. Assessment of the effects of intramuscular administration of alfaxalone with and without medetomidine in Horsfield's tortoises (*Agronemys horsfieldii*). *Vet Anaesth Analg* 2013;40(6):e68-75.
- Romeijer C, Beaufrière H, Lanieste D, Birch SM, MacKenzie S, Melville L, Moens N. Vomiting and gastrointestinal obstruction in a red-footed tortoise (*Chelonia carbonaria*). *J Herpetol Med Surg* 2016;26(1–2):32-35.
- Perpiñán D, Martínez-Silvestre A, Bargaño F, Di Giuseppe M, Orós J, Costa T. Correlation between endoscopic sex determination and gonad histology in pond sliders, *Trachemys scripta* (Reptilia: Testudines: Emydidae). *Acta Herpetologica* 2016;11(1): 91-94.
- Hedley J, Woods S, Eatwell K. The use of negative pressure wound therapy following subcarapacial abscess excision in a tortoise. *J Small Anim Pract* 2013;54(11): 610-613.
- Adami C, d'Ovidio D, Casoni D. Alfaxalone-butorphanol versus alfaxalone-morphine combination for immersion anaesthesia in oriental fire-bellied toads (*Bombina orientalis*). *Lab Anim* 2016;50(3):204-211.
- Sladkovic I, Johnson RS, Vogelnest L. Evaluation of intramuscular alfaxalone in three Australian frog species (*Litoria caerulea*, *Litoria aurea*, *Litoria booroolongensis*). *J Herpetol Med Surg* 2014;24(1–2):36-42.
- McMinn MW, Leece EA. Immersion and branchial/transcutaneous irrigation anaesthesia with alfaxalone in a Mexican axolotl. *Vet Anaesth Analg* 2011;38(6):619-23.
- Baugher SH, Greenwood J, Whittam, T. Evaluation of the sedative and anaesthetic effects of five different concentrations of alfaxalone in goldfish, *Carassius auratus*. *Aquaculture* 2013;396-399:119–123.
- O'Hagan BJ, Raidal SR. Surgical removal of retrobulbar hemangioma in a goldfish (*Carassius auratus*). *Vet Clin North Am Exot Anim Pract* 2006;9(3):729-33.
- Minter LJ, Bailey KM, Harms CA, Lewbart GA, Posner LP. The efficacy of alfaxalone for immersion anaesthesia in koi carp (*Cyprinus carpio*). *Vet Anaesth Analg* 2014;41(4):398–405.
- Bugman AM, Langer PT, Hadzima E, Rivas AE, Mitchell MA. Evaluation of the anesthetic efficacy of alfaxalone in oscar fish (*Astronotus ocellatus*). *Am J Vet Res* 2016; 77(3):239-244.
- Farry T, Lau C, Keates H, McEwen M, Woldeyohannes S, Perkins N, Goodwin W. Comparison of two formulations of alfaxalone in laboratory zebrafish (*Danio rerio*) for use in immersion anaesthesia. Oral abstract. 25th International Veterinary Emergency and Critical Care Society (IVECCS) Symposium, September 7th, 2019, Washington, D.C., USA. Session 171.
- Bakko JA, Lindemann DA, Allender MC, Chinnadurai SK. Evaluation of the anesthetic and cardiorespiratory effects of intramuscular alfaxalone administration and isoflurane in budgerigars (*Melopsittacus undulatus*) and comparison with manual restraint. *J Am Vet Med Assoc* 2019;254(12):1427-1435.
- Escalante GC, Bakko JA, Chinnadurai SK. Comparison of the sedative effects of alfaxalone and butorphanol-midazolam administered intramuscularly in budgerigars (*Melopsittacus undulatus*). *J Av Med Surg* 2018;32(4):279-285.
- Perrin KL, Nielsen JB, Thomsen AF, Bertelsen MF. Alfaxalone anesthesia in the Bengalese finch (*Lorchura domestica*). *J Zoo Wildl Med* 2017;48(4):1146-1153.
- Villaverde-Morcholes S, Benito J, García-Sánchez R, Martín-Jurado O, Gómez de Segura IA. Comparison of isoflurane and alfaxalone (Alfaxan) for the induction of anesthesia in flamingos (*Phoenicopterus roseus*) undergoing orthopedic surgery. *J Zoo Wildl Med* 2014;45(2):361-366.
- Baldrey V. Assessment of alfaxalone as an anaesthetic induction agent in mute swans (*Cygnus olor*). Submitted in part fulfillment of the requirements for the Royal College of Veterinary Surgeons' Diploma in Zoological Medicine 2014-1-68.
- Gaudio E, Voltan L, De Benedictis GM. Alfaxalone anesthesia in Lemur catta following dexmedetomidine-butorphanol-midazolam sedation. *Vet Anaesth Analg* 2018;45(3):351-356.
- Passarelli L, Rosa MG, Gamberini M, Bakola S, Burman JK, Fattori P, Galletti C. Cortical connections of area V6aV in the macaque: a visual-input node to the eye/hand coordination system. *J Neurosci* 2011;31(5):1790-1801.
- Bakker J, Uilenreef JJ, Pelt ER, Brok HP, Remarque EJ, Langermans JA. Comparison of three different sedative-anaesthetic protocols (ketamine, ketamine-medetomidine and alfaxalone) in common marmosets (*Callithrix jacchus*). *BMC Vet Res* 2013;9:1-13.
- Ansel TV, Nour AK, Benavente-Perez A. The effect of anesthesia on blood pressure measured noninvasively by using the tail-cuff method in marmosets (*Callithrix jacchus*). *J Am Assoc Lab Anim Sci* 2016;55(5):594-600.
- Curtis C, Wichmann J, Duncker S, Windt H, Hoymann HG, Lauenstein HD, Hohlfeld J, Becker T, Kaup FJ, Braun A, Knauf S. Airway hyper-responsiveness in *Ippolopsis saccharide*-challenged common marmosets (*Callithrix jacchus*). *Clin Sci* 2014 126(2):155-62.
- Sadoun A, Strelnikov K, Bonté E, Fonta C, Girard P. Cognitive impairment in a young marmoset reveals lateral ventriculomegaly and a mild hippocampal atrophy: a case report. *Sci Rep* 2015;5(16046):1-11.
- Thomas AA, Leach MC, Hedckne PA. An alternative method of endotracheal intubation of common marmosets (*Callithrix jacchus*). *Lab Anim* 2012;46(1):71-76.
- Tremblay JL, Kerton A, Gsell W. Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare. *ANIMMS Res* 2012;2(44):1-23.
- Sriarachavatana P, Ayers JD, Kendall LV. Anesthetic activity of alfaxalone compared with ketamine in mice. *J Am Assoc Lab Anim Sci* 2016;55(4):426-30.
- Higuchi S, Yamada R, Hashimoto A, Miyoshi K, Yamashita K, Ohsugi T. Evaluation of a combination of alfaxalone with medetomidine and butorphanol for inducing surgical anesthesia in laboratory mice. *Jpn J Vet Res* 2016;64(2):131-139.
- Lau C, Ranasinghe MG, Shields I, Keates H, Padoske K, Bellingham MC. Plasma pharmacokinetics of alfaxalone after a single intraperitoneal or intravenous injection of Alfaxan® in rats. *J Vet Pharmacol Ther* 2013;36(5):516-20.
- Reynolds PS, Song SK, Tamariz FJ, Barbee RW. Hypertension and vulnerability to hemorrhagic shock in a rat model. *Shock* 2015;43(2):148-156.
- Arenillas M, Gomez de Segura IA. Anaesthetic effects of alfaxalone administered intraperitoneally alone or combined with dexmedetomidine and fentanyl in the rat. *Lab Anim* 2018;52(6):588-598.
- White KL, Paine S, Harris J. A clinical evaluation of the pharmacokinetics and pharmacodynamics of intravenous alfaxalone in cyclodextrin in male and female rats following a loading dose and constant rate infusion. *Vet Anaesth Analg* 2017;44(4):865-875.
- d'Ovidio D, Marino F, Novello E, Lanaro E, Monticelli P, Adami C. Sedative effects of intramuscular alfaxalone in pet guinea pigs (*Cavia porcellus*). *Vet Anaesth Analg* 2018;45(2):183-189.
- Doerning CM, Bradley MP, Lester PA, Nowland MH. Effects of subcutaneous alfaxalone alone and in combination with dexmedetomidine and buprenorphine in guinea pigs (*Cavia porcellus*). *Vet Anaesth Analg* 2018;45(5):658-666.
- Berrier M, Langlois I, Dunn M, Helle P, Burns P, Gara-Bovnin C. Cytological analysis of bronchoalveolar lavage fluid acquired by bronchoscopy in healthy ferrets: A pilot study. *Can J Vet Res* 2016;80(1):74-80.
- Thas I. Acquired salivary mucoceles in two domestic ferrets (*Mustela putorius furo*). *Vet Rec Case Rep* 2014; 2:1-8.
- Giral M, Garcia-Olmo DC, Gómez-Juárez M, Gómez de Segura IA. Anaesthetic effects in the ferret of alfaxalone and in combination with medetomidine or tramadol: a pilot study. *Lab Anim* 2014;48(4):313-320.
- Vogelnest L. Marsupials (Marsupials). *Fowler's Zoo and Wild Animal Medicine*. 2014; Volume 8, Chapter 33, p.260.
- McInnes LM, Gillett A, Ryan UM, Austen J, Campbell RS, Hanger J, Reid SA. Trypanosoma irwini n. sp. (Sarcomastigophora: Trypanosomatidae) from the koala (*Phascolarctos cinereus*). *Parasitology* 2009;136(8):875-885.
- McInnes LM, Hanger J, Simmons G, Reid SA, Ryan UM. Novel trypanosome Trypanosoma gilletti sp. (Euglenozoa: Trypanosomatidae) and the extension of the host range of Trypanosoma copemani to include the koala (*Phascolarctos cinereus*). *Parasitology* 2011;138(1):59-70.
- McInnes LM, Gillett A, Hanger J, Reid SA, Ryan UM. The potential impact of native Australian trypanosome infections on the health of koalas (*Phascolarctos cinereus*). *Parasitology* 2011;138(7):873-883.
- Markey B, Wan C, Hanger J, Phillips C, Timms P. Use of quantitative real-time PCR to monitor the shedding and treatment of chlamydiae in the koala (*Phascolarctos cinereus*). *Vet Microbiol* 2007;120(3-4):334-342.
- Waucho C, Khan SA, Carver S, Hanger J, Loader J, Polkinghorne A, Beagley K, Timms P. A prototype recombinant-protein based Chlamydia pecorum vaccine results in reduced chlamydial burden and less clinical disease in free-ranging koalas (*Phascolarctos cinereus*). *PLoS One* 2016;11(1):1-9.
- Liddle V, Narango C, Bernays M. Anterior chamber collapse syndrome in a koala. *Aust Vet J* 2014;92(5):179-182.
- Bouts T, Karunaratna D, Berry K, Dodds J, Gashways F, Routh A, Taylor P. Evaluation of medetomidine-alfaxalone and medetomidine-ketamine in semi-free ranging Bennett's wallabies (*Macropus rufogriseus*). *J Zoo Wildl Med* 2011;42(4):617-622.
- del Álamo AM, Mandasager RE, Rieboldi TW, Payton ME. Evaluation of intravenous administration of alfaxalone, propofol, and ketamine-diazepam for anesthesia in alpacas. *Vet Anaesth Analg* 2015;42(1):72-82.

Revised: April 2023

471645A&P